TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1371323

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6388803

Group type: EXPERIMENTAL
Intervention: Irradiation combined with 5-fluorouracil and methotrexate
Number of subjects: 34
Study: 30079583

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 45
Study: 27417017

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, applied twice daily for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 24155106

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.2 g of elemental calcium in the form of calcium carbonate)
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (in women taking at least 80% of the supplements)
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: High calcium intake (diet and supplements)
Number of subjects: 1103
Study: 23518156

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted TIV
Number of subjects: 43802

Group type: COMPARATOR
Intervention: Non-adjuvanted TIV
Number of subjects: 43802
Study: 20350027

Group type: EXPERIMENTAL
Intervention: Fast Track PATHS curriculum and teacher consultation
Number of subjects: 2937

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2937
Study: 17949683

Group type: EXPERIMENTAL
Intervention: Full‐Acceptance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Full‐Distraction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Instruction‐only‐Acceptance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Instruction‐only‐Distraction
Number of subjects: 80

Group type: COMPARATOR
Intervention: No‐Instructions
Number of subjects: 80
Study: 16626610

Group type: EXPERIMENTAL
Intervention: Chart presenting pregnancy risk (continuum ranking)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Chart presenting pregnancy risk (other 2 charts)
Number of subjects: 900
Study: 12644943

Group type: EXPERIMENTAL
Intervention: Betaxolol drops
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 356
Study: 10861704

Group type: EXPERIMENTAL
Intervention: Laser 1 (9.12 Hz)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Laser 2 (73 Hz)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 9175948

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1 x 10 mg/kg, followed by 5 mg/kg 24 and 48 hours later
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indomethacin 3 x 0.2 mg/kg at 12 hour intervals
Number of subjects: 40
Study: 1493229

Group type: EXPERIMENTAL
Intervention: Deviant tone pairs (p=15%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tone pairs (p=85%)
Number of subjects: 0
Study: 3547369

Group type: EXPERIMENTAL
Intervention: Ceforanide (two 1 gm doses)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cephalothin (five doses)
Number of subjects: 101
Study: 29649021

Group type: EXPERIMENTAL
Intervention: Early mobilization intervention (in-bed cycling)
Number of subjects: 37
Study: 27144905

Group type: EXPERIMENTAL
Intervention: High-dose prednisone (60 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose prednisone (15 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Medium-dose prednisone (30 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard HF care alone
Number of subjects: 38
Study: 24915838

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 425
Study: 22460228

Group type: EXPERIMENTAL
Intervention: Next-step counseling (NSC)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Neutral assessment (NA)
Number of subjects: 2000
Study: 21294416

Group type: EXPERIMENTAL
Intervention: 600 mg noni extract
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 150 mg noni extract
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 300 mg noni extract
Number of subjects: 100
Study: 18051010

Group type: EXPERIMENTAL
Intervention: Cast Ni‐Cr alloy dowel‐core with no ferrule (Group A1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cast Ni‐Cr alloy dowel‐core with 2.0 mm ferrule (Group A2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prefabricated carbon fiber‐reinforced dowel‐resin core with no ferrule (Group B1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Carbon fiber‐reinforced dowel‐resin core with 2.0 mm ferrule (Group B2)
Number of subjects: 32
Study: 16042639

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (bup-nx)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 344
Study: 10950411

Group type: EXPERIMENTAL
Intervention: Transscleral diode laser
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 120
Study: 9287259

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 92
Study: 8346727

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 50
Study: 3730529

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg (innovator dosage form)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg (generic dosage form)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg (solution dosage form)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29726071

Group type: EXPERIMENTAL
Intervention: Gallium-68-PSMA-11 PET/CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional imaging (CT of abdomen/pelvis and bone scintigraphy with SPECT/CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT
Number of subjects: 0
Study: 27661469

Group type: EXPERIMENTAL
Intervention: Chair Yoga (CY)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Health Education Program (HEP)
Number of subjects: 100
Study: 23924290

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) at 0.3 mg/kg twice daily for 2 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study: 21590656

Group type: EXPERIMENTAL
Intervention: Closed technique (group A, n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open technique (group B, n=52)
Number of subjects: 104
Study: 18377134

Group type: EXPERIMENTAL
Intervention: Multicomponent social support intervention
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard-of-care counseling
Number of subjects: 226
Study: 16926668

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise programme (12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (seated, no exercise)
Number of subjects: 60
Study: 14668066

Group type: EXPERIMENTAL
Intervention: Brief leaflet
Number of subjects: 172

Group type: COMPARATOR
Intervention: Extended leaflet
Number of subjects: 172

Group type: COMPARATOR
Intervention: No leaflet
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both leaflets
Number of subjects: 172
Study: 10867042

Group type: EXPERIMENTAL
Intervention: Tomato juice (330 mL/d, 47.1 mg/d lycopene)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 53
Study: 9434064

Group type: EXPERIMENTAL
Intervention: prednisolone + azathioprine + cyclosporin (PAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: prednisolone + cyclosporin (PC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: prednisolone + azathioprine (PA)
Number of subjects: 0
Study: 8104724

Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) block
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Spinal block
Number of subjects: 75

Group type: COMPARATOR
Intervention: Epidural block
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural morphine 4.0 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.4 mg
Number of subjects: 75
Study: 3661279

Group type: EXPERIMENTAL
Intervention: Advice to quit given by a smoking physician model
Number of subjects: 54

Group type: COMPARATOR
Intervention: Advice to quit given by a nonsmoking physician model
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Advice to quit
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Model behavior (smoking or nonsmoking)
Number of subjects: 54
Study: 29763713

Group type: EXPERIMENTAL
Intervention: TTM33 (33°C)
Number of subjects: 567

Group type: COMPARATOR
Intervention: TTM36 (36°C)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation settings
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Respiratory rate
Number of subjects: 567
Study: 27009108

Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg twice a day for 4 weeks, then 10 μg twice a day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30
Number of subjects: 150
Study: 24748348

Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonadaptive working memory training with low memory loads
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study: 23901094

Group type: EXPERIMENTAL
Intervention: Daily acyclovir 400 mg twice daily
Number of subjects: 911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study: 20141265

Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpsychodynamic therapies
Number of subjects: 0
Study: 18622273

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 20823824

Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml/day intravenous for 10 days, then 2 tablets twice a day for 25 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Basic therapy only (comparison group)
Number of subjects: 30
Study: 15840055

Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 microg PO daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin 200 IU every other day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 11964564

Group type: EXPERIMENTAL
Intervention: 4‐Methylpyrazole (10‐15 mg/kg orally)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 9548634

Group type: EXPERIMENTAL
Intervention: Drug-free detention treatment program (DVA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (42 male inmates from other wings)
Number of subjects: 86
Study: 7846294

Group type: EXPERIMENTAL
Intervention: Cholecystokinin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 8
Study: 2850322

Group type: EXPERIMENTAL
Intervention: LMW heparin (Fluxum) at doses of 4,000 or 8,000 I.U. Axa once a day by subcutaneous injection
Number of subjects: 610

Group type: COMPARATOR
Intervention: Calcium heparin at doses of 5,000 I.U. two or three times a day by subcutaneous injection
Number of subjects: 610
Study: 31721026

Group type: EXPERIMENTAL
Intervention: Metformin treatment for 1 year
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (other hypoglycemic agents) for 1 year
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 26362578

Group type: EXPERIMENTAL
Intervention: ω‐3 polyunsaturated fatty acids (PUFAs) 1.2 g/day for 12 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 26617271

Group type: EXPERIMENTAL
Intervention: Fennel 5% vaginal cream (5 g/day for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24725898

Group type: EXPERIMENTAL
Intervention: Immobilization in abduction and external rotation (AbER, n = 51) with a stabilizer brace
Number of subjects: 102

Group type: COMPARATOR
Intervention: Immobilization in adduction and internal rotation (AdIR, n = 51) using sling and swathe bandage
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Immobilization in abduction and external rotation (AbER)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Immobilization in adduction and internal rotation (AdIR)
Number of subjects: 102
Study: 24159791

Group type: EXPERIMENTAL
Intervention: Mexicor used in combined therapy with statins for atherogenic dyslipidemia
Number of subjects: 0
Study: 20564380

Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) treatment (28-30 mg/kg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18818707

Group type: EXPERIMENTAL
Intervention: Standard risk patients who relapsed
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Patients experiencing early relapse (less than 18 months from initial diagnosis)
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Age (10+ years), presence of central nervous system disease at diagnosis, male gender, and T-cell disease
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Relapsed patients in earlier vs later era trials
Number of subjects: 1961
Study: 16835378

Group type: EXPERIMENTAL
Intervention: Palifermin (40 mug/kg per day for cohort 1, 60 mug/kg per day for cohorts 2 and 3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12509613

Group type: EXPERIMENTAL
Intervention: Clenoliximab (0.05, 0.2, 1, 5, 10 or 15 mg/kg; 150 or 350 mg weekly x 4; or 350 or 700 mg every other week x 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clenoliximab (higher doses, less frequently)
Number of subjects: 12
Study: 11100963

Group type: EXPERIMENTAL
Intervention: Protein-repair therapy including naturally occurring compounds (isoflavonoids), aminoglycoside antibiotics, butyrate analogues, phosphodiesterase inhibitors, adenosine nucleotides, designer compounds (benzo[c]quinoliziniums), small peptide replacements
Number of subjects: 0
Study: 8763312

Group type: EXPERIMENTAL
Intervention: Elastic polypropylene suture
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nylon control suture
Number of subjects: 44
Study: 2072085

Group type: EXPERIMENTAL
Intervention: Person condition (N = 12) - infants presented with tongue protrusions and mouth openings modeled by an adult.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Object condition (N = 15) - infants presented with gestures simulated by two objects.
Number of subjects: 27
Study: 6414955

Group type: EXPERIMENTAL
Intervention: Deroctyl (sustained-release capsules)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Euglucon (regular tablets)
Number of subjects: 8
Study: 31536162

Group type: EXPERIMENTAL
Intervention: Laser + RAP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Laser-Only
Number of subjects: 21
Study: 30348227

Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) implementation support intervention for CHOICE
Number of subjects: 29

Group type: COMPARATOR
Intervention: CHOICE (control group)
Number of subjects: 29
Study: 26961114

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (target LDL-C <70 mg/dL)
Number of subjects: 5144

Group type: COMPARATOR
Intervention: Standard statin therapy (target LDL-C ≥100 and <120 mg/dL)
Number of subjects: 5144
Study: 24760537

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 or 900 μg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasireotide treatment
Number of subjects: 0
Study: 21547371

Group type: EXPERIMENTAL
Intervention: Very preterm children
Number of subjects: 132

Group type: COMPARATOR
Intervention: Term children
Number of subjects: 132
Study: 20537049

Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Non-adaptive working memory training
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 17681027

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control population
Number of subjects: 20
Study: 15649196

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 8 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 200
Study: 15144165

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) principles and methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 11165454

Group type: EXPERIMENTAL
Intervention: Oats (3 gm beta-glucan)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wheat cereal (placebo)
Number of subjects: 50
Study: 9314627

Group type: EXPERIMENTAL
Intervention: PATHWAYS weight loss program (14 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 39
Study: 8157043

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (2 mg) without oxymetazoline
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol (2 mg) with oxymetazoline
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intravenous butorphanol (2 mg)
Number of subjects: 3
Study: 3749006

Group type: EXPERIMENTAL
Intervention: Advice plus nicotine gum
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Advice
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1328
Study: 28968138

Group type: EXPERIMENTAL
Intervention: IIV4 (split-virion quadrivalent influenza vaccine)
Number of subjects: 2225

Group type: COMPARATOR
Intervention: IIV3 (trivalent inactivated influenza vaccine)
Number of subjects: 2225
Study: 26223345

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 22954645

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20692562

Group type: EXPERIMENTAL
Intervention: Transconjunctival single‐plane sclerocorneal incision
Number of subjects: 122

Group type: COMPARATOR
Intervention: Clear corneal incision (CCI)
Number of subjects: 122
Study: 17940203

Group type: EXPERIMENTAL
Intervention: epoetin alpha, epoetin beta, or darbepoetin alpha (DAR) with or without granulocyte colony‐stimulating factor
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: epoetin or DAR treatment
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: less than 10% blasts, low and int‐1 International Prognostic Scoring System (IPSS), red blood cell transfusion independence, serum EPO level less than 200 IU/L
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: major response (IWG 2000 criteria), IPSS low to INT‐1, blasts less than 5%, absence of multilineage dysplasia
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: IWG 2000 minor responders
Number of subjects: 403
Study: 15908852

Group type: EXPERIMENTAL
Intervention: Chronically homeless (CH)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Transitionally homeless (TRANS)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Housed comparison subjects (HSD)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Housing status
Number of subjects: 274
Study: 12554890

Group type: EXPERIMENTAL
Intervention: Breathing retraining
Number of subjects: 33

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 33
Study: 10443731

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with pelvic lymph node dissection
Number of subjects: 95

Group type: COMPARATOR
Intervention: External beam radiotherapy with endocrine therapy
Number of subjects: 95
Study: 7603934

Group type: EXPERIMENTAL
Intervention: Mastery tape
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Coping tape
Number of subjects: 42

Group type: COMPARATOR
Intervention: General nurse scenes and narration tape
Number of subjects: 42
Study: 2192098

Group type: EXPERIMENTAL
Intervention: Oxprenolol (160 mg initially, 320 mg subsequently)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (50 mg daily)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol (160 mg and 320 mg) and chlorthalidone (25 mg and 50 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Oxprenolol (monotherapy and combination therapy)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (monotherapy)
Number of subjects: 62
Study: 343970

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 12

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 12
Study: 29017289

Group type: EXPERIMENTAL
Intervention: Precaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EMLA mixture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4% Lignocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% Lignocaine
Number of subjects: 80
Study: 27145248

Group type: EXPERIMENTAL
Intervention: SMS reminders for medication adherence
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 96
Study: 24200515

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL) 20g daily for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (PLA) isoenergetic/isomacronutrient
Number of subjects: 53
Study: 22778317

Group type: EXPERIMENTAL
Intervention: First-line erlotinib followed at progression by cisplatin-gemcitabine
Number of subjects: 760

Group type: COMPARATOR
Intervention: Standard treatment (first-line chemotherapy followed by erlotinib)
Number of subjects: 760
Study: 21126943

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (healthy women)
Number of subjects: 24
Study: 18275764

Group type: EXPERIMENTAL
Intervention: Intensive and multifactorial intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 15818105

Group type: EXPERIMENTAL
Intervention: Norepinephrine to increase mean arterial pressure to 85 mm Hg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mean arterial pressure maintained at 65 mm Hg (Control group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Norepinephrine to maintain mean arterial pressure at 65 mm Hg (Control group)
Number of subjects: 28